ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker?
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Gallbladder cancer: Progress in the Indian subcontinent.World journal of clinical oncology · 2024Review
- A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death.Journal of the American Chemical Society · 2023Article
- Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing.Clinical and translational medicine · 2021Article
- The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models.Carcinogenesis · 2018Article
- Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma.Royal Society open science · 2018Article
- Expression Analysis of Survivin and XIAP in Gallbladder Cancer: a Case-control Study in Indo-Gangetic Plain.Journal of gastrointestinal cancer · 2018Article
- Chemopreventive Effect of Aster glehni on Inflammation-Induced Colorectal Carcinogenesis in Mice.Nutrients · 2018Article
- Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Cellular & molecular biology letters · 2017Review
- Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells.Cancer cell international · 2017Article
- RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma.Oncotarget · 2015Article
- Article
- Comparison of customized spin-column and salt-precipitation finger-prick blood DNA extraction.Bioscience reports · 2014Article
- Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study.Medical oncology (Northwood, London, England) · 2014Article
- Survivin and insulin-like growth factor-I: potential role in the pathogenesis of acne and post-acne scar.Scars, burns & healingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin, an inhibitor of apoptosis, has been shown to be expressed in various malignancies. However, its role in gallbladder cancer (GBC) has not been evaluated yet. We investigated its expression in peripheral blood of patients with gallbladder diseases (gallstone disease (GSD), n = 30; GBC, n = 39) and compared with healthy controls (n = 25). Survivin expression was correlated with clinicopathological parameters, diagnosis, and prognosis of patients with GBC. Expression of survivin messenger RNA (mRNA) in blood was evaluated by real-time PCR. Significantly higher (P < 0.0001) expression of survivin mRNA was observed in GBC (2.2-fold) and GSD (1.52-fold) as compared to control. In GBC, increased survivin expression was significantly associated with higher tumor stage (stage III vs. stage II; P < 0.0001) and tumor differentiation (poor and moderate vs. well differentiated; P < 0.0001). No significant correlation was observed with any of the other clinicopathological parameters (age, gender, and presence or absence of gallstones) studied. Cutoff value of survivin mRNA relative quantification (RQ) was 1.08, with a sensitivity of 98.55 % and specificity of 100 % for the diseased group (GSD or GBC). RQ value of 1.71 differentiated GBC from GSD with a sensitivity of 89.74 % and specificity of 100 %. Increased expression of survivin was associated with a shorter median overall survival (12 vs. 18 months) in GBC patients. Differential expression of survivin in GBC suggests its possible role and association with poor prognosis. Expression of survivin in peripheral blood could be useful both in the diagnosis and prognosis of GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.